Claims for Patent: 7,829,300

Summary for Patent: 7,829,300

Title:	Method of measuring the activity of G(alpha)i- or G(alpha)o-coupled receptors using Ca.sup.2+ influx in cells
Abstract:	A method of measuring the activation or deactivation of G(alpha)i- or G(alpha)o-coupled receptors, and methods of identifying agonists or antagonists of such receptors.
Inventor(s):	Wade; Erik James (Aachen, DE), Janocha; Elke (Linnich, DE), Germann; Tieno (Aachen, DE)
Assignee:	Gruenenthal GmbH (Aachen, DE)
Application Number:	12/336,025
Patent Claims:	1. A method of measuring the activation of a G(alpha)i-and/or G(alpha)o-coupled receptor in cells that express at least one G(alpha)q-coupled receptor, said method comprising: (a) simultaneously treating the cells with an amount of an agonist of the G(alpha)q-coupled receptor such that a sub-threshold activity is obtained, and with an agonist of the G(alpha)i- and/or G(alpha)o-coupled receptor, and (b) measuring the cytoplasmic Ca.sup.2+ concentration of the cells, wherein the amount of the agonist of the G(alpha)q-coupled receptor that produces a sub-threshold activity is that amount at which the ratio of: (i) the result of the measurement of the cytoplasmic Ca.sup.2+ concentration of the cells on treatment with an amount of the agonist of the G(alpha)q-coupled receptor to (ii) the result of the measurement of the cytoplasmic Ca.sup.2+ concentration of the cells on simultaneous treatment of the cells with the same amount of the agonist of the G(alpha)q-coupled receptor and an amount of an agonist of the G(alpha)i- and/or G(alpha)o-coupled receptor that is sufficient for complete activation, does not exceed about 1:20. 2. A method of identifying agonists of a G(alpha)i- and/or G(alpha)o-coupled receptor, said method comprising: (i) providing cells that express the G(alpha)i- and/or G(alpha)o-coupled receptor and at least one G(alpha)q-coupled receptor; and (ii) carrying out steps (a) and (b) of the method according to claim 1, wherein a test substance, whose activity in respect of the G(alpha)i- and/or G(alpha)o-coupled receptor is to be tested, is used in step (a) as the agonist of the G(alpha)i- and/or G(alpha)o-coupled receptor. 3. A method according to claim 1, wherein before step (a) the amount of the agonist of the G(alpha)q-coupled receptor that gives a sub-threshold activity is determined by: (1) treating the cells with different amounts of the agonist of the G(alpha)q-coupled receptor; (2) measuring the cytoplasmic Ca.sup.2+ concentration of the cells for each amount of the agonist of step (1); (3) simultaneously treating the cells with different amounts of the agonist of the G(alpha)q-coupled receptor and with a constant amount of the agonist of the G(alpha)i- and/or G(alpha)o-coupled receptor sufficient for complete activation of the receptor; (4) measuring the cytoplasmic Ca.sup.2+ concentration of the cells for each amount of the agonist of the G(alpha)q-coupled receptor of step (3); and (5) comparing the results of the measurements of steps (2) and (4) for equal amounts of the agonist of the G(alpha)q-coupled receptor. 4. A method according to claim 3, wherein step (5) comprises calculating a ratio from the results of the measurements of steps (2) and (4). 5. A method according to claim 4, wherein the amount of the agonist of the G(alpha)q-coupled receptor is that amount at which a ratio of the result of the measurement of step (2) to the result of the measurement of step (4) of not more than about 1:20 is obtained. 6. A method according to claim 1, wherein the measurement of the cytoplasmic Ca.sup.2+ concentration is carried out using a Ca.sup.2+-dependent dye. 7. A method according to claim 6, wherein the dye is a fluorescent dye. 8. A method according to claim 7, wherein the fluorescent dye is selected from the group consisting of molecules of the families fura, indo, quin, coumarinbenzothiazoles, fluo, calcium green, Oregon green, calcium orange, calcium crimson, magnesium green, rhod and X-rhod. 9. A method according to claim 1, wherein the G(alpha)i- or G(alpha)o-coupled receptor is selected from the group consisting of opioid receptors, P2Y12, receptors of the Edg family, GABA-B, muscarine-M2, -M4, dopamine-D2, -D3, -D4, histamine-H3 receptors, receptors of the serotonin-H1 family, C3a, C5a, fMLP, CXCR1-5, CCR1-9, XCR1, CX3CR1, neuropeptide-Y1 to 6, somatostatin-Sst2 receptors, chemoattractant R-homologous molecule expressed on Th2 cells, prostaglandin-E type 3, adenosine-A1 and adenosine-A3 receptors. 10. A method according to claim 1, wherein the G(alpha)q-coupled receptor is selected from the group consisting of muscarine-M1, -M3, -M5, serotonin-H2, bombesin, cholecystokinin, neurokinin, prostaglandin-E type I, adenosine-A2B, P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, calcitonin, mGluR1 receptors, angiotensin II receptor 1, protease activated receptor 1 and serotonin R. 11. A method according to claim 1, wherein at least one of the G(alpha)i-coupled receptor, the G(alpha)o-coupled receptor and the G(alpha)q-coupled receptor is expressed endogenously by the cells. 12. A method according to claim 1, wherein the cells have been transfected with a nucleic acid construct for expression of at least one receptor selected from the group consisting of the G(alpha)i-coupled receptor, the G(alpha)o-coupled receptor and the G(alpha)q-coupled receptor. 13. A method according to claim 1, wherein the cells are selected from the group consisting of stable cell lines, primary cell cultures and tissue cells. 14. A method according to claim 13, wherein the cell line is selected from the group consisting of CHO, HEK293, THP-1, SH-SY5Y, Jurkat, HeLa, L cells, A-10, Cos-7, NIH 3T3, ECV304, RBL, UMR 106, PC3, GH3, PC1 and IMR-32. 15. A method according to claim 1, wherein the agonist of the G(alpha)q-coupled receptor is selected from the group consisting of adenosine, AMP, ADP, ATP, uridine, UMP, UDP, UTP, cytosine, CMP, CDP, CTP, guanosine, GMP, GDP, GTP, thymidine, TMP, TDP, TTP, inosine, IMP, IDP and ITP and muscarine receptor agonists. 16. A method according to claim 1, wherein the agonist of the G(alpha)i- and/or G(alpha)o-coupled receptor is selected from the group consisting of GRT0777S, Damgo, fentanyl, serotonin and morphines. 17. A method of measuring the deactivation of a G(alpha)i-and/or G(alpha)o-coupled receptor in cells that express at least one G(alpha)q-coupled receptor, said method comprising: (A) simultaneously treating the cells with an amount of an agonist of the G(alpha)q-coupled receptor such that a sub-threshold activity is obtained, and with an amount of an agonist of the G(alpha)i- and/or G(alpha)o-coupled receptor which is just sufficient for complete activation; (B) measuring the cytoplasmic Ca.sup.2+ concentration of the cells; (C) simultaneously treating the cells with the same amount as in step (A) of the agonist of the G(alpha)q-coupled receptor, with the same amount as in step (A) of the agonist of the G(alpha)i- and/or G(alpha)o-coupled receptor and with an antagonist of the G(alpha)i-and/or G(alpha)o-coupled receptor; (D) measuring the cytoplasmic Ca.sup.2+ concentration of the cells; and (E) comparing the results from the measurements of steps (B) and (D); wherein the amount of the agonist of the G(alpha)q-coupled receptor that gives a sub-threshold activity is that amount at which the ratio of: (i) the result of the measurement of the cytoplasmic Ca.sup.2+ concentration of the cells on treatment with an amount of the agonist of the G(alpha)q-coupled receptor to (ii) the result of the measurement of the cytoplasmic Ca.sup.2+ concentration of the cells on simultaneous treatment of the cells with the same amount of the agonist of the G(alpha)q-coupled receptor and an amount of an agonist of the G(alpha)i- and/or G(alpha)o-coupled receptor that is sufficient for complete activation, does not exceed about 1:20. 18. A method of identifying antagonists of a G(alpha)i- and/or G(alpha)o-coupled receptor, said method comprising: (I) providing cells that express the G(alpha)i- and/or G(alpha)o-coupled receptor and at least one G(alpha)q-coupled receptor; and (II) carrying out steps (A) to (E) of the method according to claim 17, wherein a test substance, whose activity in respect of the G(alpha)i- and/or G(alpha)o-coupled receptor is to be tested is used as the antagonist of the G(alpha)i- and/or G(alpha)o-coupled receptor in step (C). 19. A method according to claim 17, wherein before step (A) the amount of the agonist of the G(alpha)q-coupled receptor that gives a sub-threshold activity is determined by: (1) treating the cells with different amounts of the agonist of the G(alpha)q-coupled receptor; (2) measuring the cytoplasmic Ca.sup.2+ concentration of the cells for each amount of the agonist of step (1); (3) simultaneously treating the cells with different amounts of the agonist of the G(alpha)q-coupled receptor and with a constant amount of the agonist of the G(alpha)i- and/or G(alpha)o-coupled receptor sufficient for complete activation of the receptor; (4) measuring the cytoplasmic Ca.sup.2+ concentration of the cells for each amount of the agonist of the G(alpha)q-coupled receptor of step (3); and (5) comparing the results of the measurements of steps (2) and (4) for equal amounts of the agonist of the G(alpha)q-coupled receptor. 20. A method according to claim 19, wherein step (5) comprises calculating a ratio from the results of the measurements of steps (2) and (4). 21. A method according to claim 20, wherein the amount of the agonist of the G(alpha)q-coupled receptor is that amount at which a ratio of the result of the measurement of step (2) to the result of the measurement of step (4) of not more than about 1:20 is obtained. 22. A method according to claim 17, wherein the measurement of the cytoplasmic Ca.sup.2+ concentration is carried out using a Ca.sup.2+-dependent dye. 23. A method according to claim 22, wherein the dye is a fluorescent dye. 24. A method according to claim 23, wherein the fluorescent dye is selected from the group consisting of molecules of the families fura, indo, quin, coumarinbenzothiazoles, fluo, calcium green, Oregon green, calcium orange, calcium crimson, magnesium green, rhod and X-rhod. 25. A method according to claim 17, wherein the G(alpha)i- or G(alpha)o-coupled receptor is selected from the group consisting of opioid receptors, P2Y12, receptors of the Edg family, GABA-B, muscarine-M2, -M4, dopamine-D2, -D3, -D4, histamine-H3 receptors, receptors of the serotonin-H1 family, C3a, C5a, fMLP, CXCR1-5, CCR1-9, XCR1, CX3CR1, neuropeptide-Y1 to 6, somatostatin-Sst2 receptors, chemoattractant R-homologous molecule expressed on Th2 cells, prostaglandin-E type 3, adenosine-A1 and adenosine-A3 receptors. 26. A method according to claim 17, wherein the G(alpha)q-coupled receptor is selected from the group consisting of muscarine-M1, -M3, -M5, serotonin-H2, bombesin, cholecystokinin, neurokinin, prostaglandin-E type I, adenosine-A2B, P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, calcitonin, mGluR1 receptors, angiotensin II receptor 1, protease activated receptor 1 and serotonin R. 27. A method according to claim 17, wherein at least one of the G(alpha)i-coupled receptor, the G(alpha)o-coupled receptor and the G(alpha)q-coupled receptor is expressed endogenously by the cells. 28. A method according to claim 3, wherein the cells have been transfected with a nucleic acid construct for expression of at least one receptor selected from the group consisting of the G(alpha)i-coupled receptor, the G(alpha)o-coupled receptor and the G(alpha)q-coupled receptor. 29. A method according to claim 17, wherein the cells are selected from the group consisting of stable cell lines, primary cell cultures and tissue cells. 30. A method according to claim 29, wherein the cell line is selected from the group consisting of CHO, HEK293, THP-1, SH-SY5Y, Jurkat, HeLa, L cells, A-10, Cos-7, NIH 3T3, ECV304, RBL, UMR 106, PC3, GH3, PC1 and IMR-32. 31. A method according to claim 17, wherein the agonist of the G(alpha)q-coupled receptor is selected from the group consisting of adenosine, AMP, ADP, ATP, uridine, UMP, UDP, UTP, cytosine, CMP, CDP, CTP, guanosine, GMP, GDP, GTP, thymidine, TMP, TDP, TTP, inosine, IMP, IDP and ITP and muscarine receptor agonists. 32. A method according to claim 17, wherein the agonist of the G(alpha)i- and/or G(alpha)o-coupled receptor is selected from the group consisting of GRT0777S, Damgo, fentanyl, serotonin and morphines. 33. A method according to claim 17, wherein the antagonist of the G(alpha)i- and/or G(alpha)o-coupled receptor is naloxone.

Details for Patent 7,829,300

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2022-12-05